UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Leukemia, 2015-05, Vol.29 (5), p.1123-1132

2015

Link zum Volltext

Verfügbarkeit prüfen

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Leukemia, 2017-11, Vol.31 (11), p.2398-2406

2017

Link zum Volltext

Verfügbarkeit prüfen

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

Leukemia, 2016-06, Vol.30 (6), p.1255-1262

2016

Link zum Volltext

Verfügbarkeit prüfen

Impact of withdrawal of antiepileptic medication on the duration of focal onset seizures

Seizure (London, England), 2019-04, Vol.67, p.40-44

2019

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

Leukemia, 2013-05, Vol.27 (5), p.1072-1079

2013

Link zum Volltext

Verfügbarkeit prüfen

Targeted antibiotic treatment of lame sheep with footrot using either oxytetracycline or gamithromycin

Veterinary record, 2014-01, Vol.174 (2), p.46-46

2014

Link zum Volltext

Verfügbarkeit prüfen

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia

Leukemia, 2011-09, Vol.25 (9), p.1433-1438

2011

Link zum Volltext

Verfügbarkeit prüfen

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

Leukemia, 2012-06, Vol.26 (6), p.1286-1292

2012

Link zum Volltext

Verfügbarkeit prüfen

Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study

Journal of neurology, 2013-08, Vol.260 (8), p.2046-2051

2013

Link zum Volltext

Verfügbarkeit prüfen

The IPSS-R has prognostic impact in untreated patients with MDS del(5q)

Leukemia research, 2018-09, Vol.72, p.27-33

2018

Link zum Volltext

Verfügbarkeit prüfen

Use of impregnated catheters to decrease colonization rates in neonates - A randomized controlled pilot trial

Journal of neonatal-perinatal medicine, 2020, Vol.13 (2), p.231

2020

Link zum Volltext

Verfügbarkeit prüfen

318 THE IPSS-R HAS PROGNOSTIC IMPACT IN UNTREATED PATIENTS WITH MDS DEL(5Q)

Leukemia research, 2015-04, Vol.39, p.S157-S157

2015

Link zum Volltext

Verfügbarkeit prüfen

P-101 Influence of WHO categories and gender on the prognosis of MDS del(5q) patients

Leukemia research, 2013-05, Vol.37, p.S68-S68

2013

Link zum Volltext

Verfügbarkeit prüfen

Remission status should not be treated as a base-line covariate--reply to Etienne et al

Haematologica (Roma), 2014-09, Vol.99 (9), p.e174-e175

2014

Link zum Volltext

Verfügbarkeit prüfen

P14.02 Influence of individual CpG methylation status on outcome in adult patients with glioblastoma multiforme receiving alkylating agent treatment

Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (Supplement_3), p.iii66-iii66

2019

Link zum Volltext

Verfügbarkeit prüfen

Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY

Leukemia research, 2023-05, Vol.128, p.107224, Article 107224

2023

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del

Leukemia, 2013-05, Vol.27 (5), p.1072

2013

Link zum Volltext

Verfügbarkeit prüfen

Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82

Haematologica (Roma), 2012-05, Vol.97 (5), p.e14-e15

2012

Link zum Volltext

Verfügbarkeit prüfen

Effect of cytogenetics at diagnosis on outcome of CML: Results from the randomized German CML Study IV

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6553-6553

2011

Link zum Volltext

Verfügbarkeit prüfen

Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg ± IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.6517-6517

2010

Link zum Volltext

Verfügbarkeit prüfen

Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1,025 patients

Phlebology, 2009-06, Vol.24 (3), p.131

2009

Link zum Volltext

Verfügbarkeit prüfen

CCL1 is a major regulatory T cell attracting factor in human breast cancer

BMC cancer, 2018-12, Vol.18 (1), p.1278-1278, Article 1278

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(59)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(22)
Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Female
(18)
Male
(18)
Aged
(15)
Hematology
(15)
Middle Aged
(15)
Adult
(13)
Aged, 80 And Over
(13)
Oncology
(13)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(12)
Treatment Outcome
(10)
Adolescent
(9)
Chronic Myeloid Leukemia
(8)
Imatinib Mesylate
(8)
Disease Progression
(7)
Risk Factors
(7)
Young Adult
(7)
Drug Therapy
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(25)
Leukemia
(9)
Journal Of Clinical Oncology
(7)
Leukemia Research
(4)
Haematologica
(3)
Annals Of Hematology
(1)
Archives Françaises De Pediatrie
(1)
Bmc Cancer
(1)
Journal Of Neonatal-Perinatal Medicine
(1)
Journal Of Neurology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

Impact of withdrawal of antiepileptic medication on the duration of focal onset seizures

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

Targeted antibiotic treatment of lame sheep with footrot using either oxytetracycline or gamithromycin

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study

The IPSS-R has prognostic impact in untreated patients with MDS del(5q)

Use of impregnated catheters to decrease colonization rates in neonates - A randomized controlled pilot trial

318 THE IPSS-R HAS PROGNOSTIC IMPACT IN UNTREATED PATIENTS WITH MDS DEL(5Q)

P-101 Influence of WHO categories and gender on the prognosis of MDS del(5q) patients

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

Remission status should not be treated as a base-line covariate--reply to Etienne et al

P14.02 Influence of individual CpG methylation status on outcome in adult patients with glioblastoma multiforme receiving alkylating agent treatment

Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del

Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82

Effect of cytogenetics at diagnosis on outcome of CML: Results from the randomized German CML Study IV

Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg ± IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV

Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1,025 patients

CCL1 is a major regulatory T cell attracting factor in human breast cancer

Suchergebnisse filtern